RedHill Biopharma (RDHL) Profit After Tax: 2009-2024
Historic Profit After Tax for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$8.3 million.
- RedHill Biopharma's Profit After Tax rose 403.13% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $11.6 million, marking a year-over-year increase of 122.61%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
- According to the latest figures from FY2024, RedHill Biopharma's Profit After Tax is -$8.3 million, which was down 134.57% from $23.9 million recorded in FY2023.
- RedHill Biopharma's 5-year Profit After Tax high stood at $23.9 million for FY2023, and its period low was -$97.7 million during FY2021.
- Over the past 3 years, RedHill Biopharma's median Profit After Tax value was -$8.3 million (recorded in 2024), while the average stood at -$18.7 million.
- Its Profit After Tax has fluctuated over the past 5 years, first surged by 133.37% in 2023, then slumped by 134.57% in 2024.
- RedHill Biopharma's Profit After Tax (Yearly) stood at -$76.2 million in 2020, then dropped by 28.32% to -$97.7 million in 2021, then increased by 26.68% to -$71.7 million in 2022, then soared by 133.37% to $23.9 million in 2023, then crashed by 134.57% to -$8.3 million in 2024.